Central effects of dibutyryl cyclic AMP and GMP on the temperature in conscious rabbits.
Intracerebroventricular (i.c.v.) administration of dibutyryl cyclic AMP (Db-cAMP)- and dibutyryl cyclic GMP (Db-cGMP)-induced hyperthermia in rabbits. Central administration of 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711), a selective inhibitor of cAMP phosphodiesterase, only accentuated the hyperthermia due to Db-cAMP whereas a selective inhibitor of cGMP phosphodiesterase, 2-O-proproxyphenyl-8-azapurin-6-one (M and B 22948), only potentiated the hyperthermia caused by Db-cGMP. The hyperthermia due to Db-cAMP and Db-cGMP was not mediated through prostaglandins (PG). In contrast, central administration of an alpha-adrenergic receptor antagonist, phenoxybenzamine, or a beta-adrenergic receptor antagonist, sotalol, only attenuated the hyperthermic response to Db-cAMP while a cholinergic muscarinic receptor antagonist, atropine, specifically antagonized Db-cGMP-induced hyperthermia. I.c.v. administration of a protein synthesis inhibitor, anisomycin, did inhibit the hyperthermia due to Db-cAMP and Db-cGMP. Opiate antagonist, naloxone, did not antagonize Db-cAMP- and Db-cGMP-induced hyperthermia. These results suggest that a protein mediator is implicated in the induction of hyperthermia by Db-cAMP and Db-cGMP and that cAMP and cGMP may be involved through alpha/beta-adrenergic and cholinergic muscarinic receptors respectively in the central regulation of heat production/conservation in rabbits.
D000818:Animals; D000841:Anisomycin / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D001833:Body Temperature Regulation / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D003994:Bucladesine / Q000494:pharmacology*; D006152:Cyclic GMP / Q000031:analogs & derivatives*; D003995:Dibutyryl Cyclic GMP / Q000494:pharmacology*; D015232:Dinoprostone; D007213:Indomethacin / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology; D011817:Rabbits; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D013015:Sotalol / Q000494:pharmacology; D014403:Tubocurarine / Q000494:pharmacology
D010726:Phosphodiesterase Inhibitors; D011458:Prostaglandins E; D017981:Receptors, Neurotransmitter; D010643:Phenoxybenzamine; D003995:Dibutyryl Cyclic GMP; D009270:Naloxone; D003994:Bucladesine; D000841:Anisomycin; D001285:Atropine; D013015:Sotalol; D006152:Cyclic GMP; D015232:Dinoprostone; D014403:Tubocurarine; D007213:Indomethacin